"I have worked with the Rx Communications team for approximately 20 years. From our days as a garage start-up, pioneering the life science real estate niche, through our IPO on the NYSE and continued growth into a multi-billion dollar company and industry leader -- Rx has been a critical advisor. We consider them members of our team, as they have worked side-by-side with us, providing counsel and helping to improve and expand our visibility and institutional ownership base. Our investors often comment on their professionalism and value, and we look forward to working with their high caliber team for years to come."
Joel S. Marcus, Chairman, Chief Executive Officer and Founder
Alexandria Real Estate Equities, Inc.
"We worked with Rx Communications Group for several years and we regard them as a trustworthy partner with excellent knowledge specifically targeted to our needs and those of our shareholders. Working with Rx is always a joy."
Peter Nielsen, President and Chief Executive Officer
Bio-Path Holdings, Inc.
"Providing only senior level counsel, Rx Communications is unique among today’s IR agencies. The firm is detail oriented and laser focused on the end goal. Their counsel and support has been instrumental over the years, as they have helped Catalyst to educate the market on its value proposition, and as they have helped us navigate through several difficult situations surrounding our ongoing product development."
Patrick J. McEnany, Co-Founder, Chairman, President and Chief Executive Officer Catalyst Pharmaceutical Partners, Inc.
"Like other of their clients, I have had the pleasure of working with Rx Communications through my tenure at two different pharmaceutical companies, through IPOs, drug trials and product launches. Staffed only with senior level counselors, Rx has an unparalleled wealth of life science industry experience and an ability to truly understand key market drivers in order to properly position the company and attract the right investors, analysts and press, to the story. Their clients stick with them, because the firm delivers. Their track record speaks for itself."
Jim Meer, Former Senior Vice President and Chief Financial Officer of Columbia Laboratories, Inc. and Treasurer of Schein Pharmaceutical, Inc.
"Rx Communications Group has proven itself to us, time and time again, providing a solid blend of analytic, valuation and communications outreach. As an example, their seamless execution of our investor relations program resulted in a doubling of our trading volume and tripling of our stock price within a period of just nine months. Their work was instrumental to the execution of our corporate growth goals."
Nancy Lurker, Former Chief Executive Officer of PDI, Inc.
“As a start-up life sciences company, we were looking for a communications firm to help develop corporate messaging that would allow us to tell our story in an articulate and succinct way, recognizing the importance of getting it right the first time. Rx Communications delivered from the outset. They were patient, took the time to thoroughly understand our value proposition, and delivered professional investor relations collateral. The talented team at Rx Communications consistently adds value, and I would recommend them highly to any health care company in need of a proactive, forward-thinking communications partner.”
Shawn Glinter, Founder and CEO, Pendant Biosciences
"Rx Communications’ deep understanding of the health care and financial markets, coupled with a keen attention to detail and ability to bring fresh ideas to the table, is only part of why I have chosen to work with the firm for more than 15 years; first at 3-Dimensional Pharmaceuticals, until its sale to Johnson & Johnson, followed by TetraLogic, and PharmAthene, until its merger with Altimmune. They are a pleasure to work with and I am delighted to have them as part of our team."
John M. Gill, Founder, President, Chief Executive Officer and Director John M. Gill, Former Chief Executive Officer of PharmAthene, Inc.
“InnoPharma retained Rx Communications with the singular goal of increasing the Company’s visibility as a potential acquisition candidate. We immediately found the Rx team to be proactive, fully engaged and possessing fresh ideas and strategy. As high level counselors, they spent time with management to review and develop our messaging, presentation and target audience. Rx prepared InnoPharma to speak at the prestigious JP Morgan Healthcare conference for the first time, where we were introduced to numerous high value targets. Just eight months after our program began, InnoPharma announced its successful acquisition by Pfizer. Goal accomplished.”
John Deighan, Senior Director – Finance, Previously InnoPharma Chief Financial Officer
Rx Communications Group, LLC
555 Madison Avenue 5th Floor New York, NY 10022